Abstract: Provided are compounds of the formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, for use in treating or suppressing a SARS-CoV-2 infection in a subject. A novel dosing regimen for administration of the disclosed compounds is also provided comprising administering at least one loading dose and at least one maintenance dose of the disclosed compound. The compounds of the disclosure are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with the dosing regimen described.